Regulation of glucose homeostasis by islet hormones.

In general, all these protective mechanisms for maintaining blood glucose concentration and prevent the liver from stream throughout the day and night, which is also essential to β cells constitutively secrete a small amount of insulin into blood energy between meals and blood glucose will rise to normal levels. In this case, stored glycogen can be used for signals the liver to break down glycogen and release glucose back into the bloodstream. Derangements of these mechanisms can lead to hypoglycemia.

**Hypoglycemia**

Hypoglycemia occurs in people of almost all ages, although the causes of hypoglycemia for infants, adults and the elderly may vary. Hypoglycemia can be classified as fasting, reactive, surreptitious, and artifactual [2,24-30]. Common causes of hypoglycemia include prolonged fasting, excessive effects of diabetic medicines, such as insulin, strenuous physical activity, or alcohol overconsumption [2,26-30].

**Fasting hypoglycemia**

Fasting hypoglycemia, which is also called post absorptive hypoglycemia, is diagnosed when a patient has low blood glucose concentration after physical activity, an overnight fast, between meals, usually 8 hours or longer in a patient after a meal. Common causes of fasting hypoglycemia include excessive effects of diabetic medications, strenuous physical activity, or alcohol overconsumption; Most cases of fasting hypoglycemia are believed to have underlying diseases (Table 1).

Insulinoma is another cause for fasting hypoglycemia and affects relatively young patients. Insulinoma is a rare neuroendocrine
tumor of the pancreas. The diagnosis of insulinoma relies on the demonstration of Whipple’s triad, consisting of symptomatic hypoglycemia, documentation of hypoglycemia and resolution of symptoms upon glucose administration as well as imaging using CT scanning, endoscopic ultrasound and octreotide scanning. Insulinoma are benign in 90% of cases, however can cause severe and even lethal hypoglycemia. The treatment is surgical resection for benign insulinoma, however 10% of insulinoma are malignant; the patients suffer horribly from uncontrollable hypoglycemia for which there is no effective treatment.

Nesidioblastosis can cause hyperinsulinemic hypoglycemia because of neoformation of Langerhans islets, and it has been recognized in both adults and infants [31,32]. In adults, nesidioblastosis is associated with Roux-en-Y gastric bypass surgery requiring recurrent hospitalizations for hypoglycemia [33-45]. Congenital nesidioblastosis is also commonly referred to as persistent hyperinsulinemic hypoglycemia of infancy. It is usually caused by a number of genetic mutations, and symptoms can range from mild to severe. Severe cases can manifest as cyanosis or seizures, which can then lead to developmental delay if brain damage occurs. Although the clinical presentation between hypoglycemia induced byinsulinoma and nesidioblastosis might be similar, the symptoms in patients with nesidioblastosis occur mainly postprandially (reactive hypoglycemia) and only rarely while fasting. In contrast, most patients with insulinoma have fasting hypoglycemia.

**Reactive hypoglycemia**

Reactive hypoglycemia, also called postprandial hypoglycemia, usually happens when blood glucose levels become dangerously low within 4 hours after a meal. Although the symptoms of reactive hypoglycemia are similar to that of fasting hypoglycemia, these two types of hypoglycemia have different causes (Table 1). It is believed that reactive hypoglycemia results from excess insulin secretion by islets following a large carbohydrate-rich meal. However, the mechanism of continuous elevated insulin secretion is still unclear. Possible causes include a pre-diabetic condition that results in improper regulation of insulin secretion or rare enzyme deficiencies that remain food undigested [46-56]. It is important to note that the symptoms of reactive hypoglycemia can occur without low blood glucose levels and therefore no immediate medical treatment is required for these cases of reactive hypoglycemia.

**Hypoglycemia and diabetes**

Diabetic hypoglycemia is diagnosed when low blood glucose concentrations of 3.9 mmol/L (70 mg/dl) or lower happen in patients with diabetes mellitus. It usually occurs as a consequence of diabetic therapies, especially exogenous insulin. Remarkably, of all the causes listed in (Table 1), hypoglycemia occurs most frequently in patients with diabetes as a result of diabetic therapies [57-59]. However, diagnosis and management of hypoglycemia in diabetic patients are quite different from non-diabetic ones [57,58,60-62].

**Diabetes mellitus**

It has been cited as one of the most challenging health problems in the US. It is a group of metabolic disorders characterized by hyperglycemia, in which the patients have very high blood glucose over a prolonged period of time, because of either inadequate insulin secretion, or improper responses to insulin, or both [63-65]. For patients with diabetes, insulin therapy and other diabetes medications are designed to decrease the high blood glucose levels back to a normal range. Over-dose of insulin or other diabetic medications can cause blood glucose level to drop too low, resulting in hypoglycemia. Therefore, diabetic hypoglycemia usually occurs as a consequence of anti-diabetic therapies in these patients. Other causes of diabetic hypoglycemia include prolonged fasting and excessive body activity without proper adjustment of food and medications.

**Hypoglycemia and T1DM:** T1DM, also known as juvenile-onset or insulin-dependent diabetes, is a type of diabetes where the auto immune attack destroys the insulin-producing β cells of the islets of Langerhans in pancreas, leading to insulin deficiency [64]. Patients with T1DM do not produce insulin, and must receive frequent insulin injections or rely on insulin pumps for continuous insulin supply [66,67]. Insulin injection for T1DM is the most common cause of severe hypoglycemia in young adults. These patients have to carefully monitor their blood glucose level and regulate insulin supply accordingly; however blood glucose levels can easily fall and result in severe hypoglycemia. Islet transplantation can potentially restore the function of islet cells and successfully stabilize glycemic control in these patients.

**Hypoglycemia and T2DM:** T2DM, also known as noninsulin-dependent diabetes mellitus or adult-onset diabetes [68], is the most common form of diabetes mellitus worldwide, accounting for more than 90% of cases. Different from to an absolute deficiency of insulin secretion from islets of pancreas in patients with T1DM, the T2DM is mainly characterized by hyperglycemia in the context of insulin resistance and relatively insufficient insulin secretion. Comparing to T1DM, patients with T2DM tend less likely to be hypoglycemic. The most common cause of hypoglycemia in T2DM is iatrogenic, which occurs when insulin analogues, insulin secret rogue drugs, or combined therapy cause blood glucose levels to fall below normal [69,70]. A retrospective review of 102 patients with diabetes reported that drug-induced hypoglycemic coma occurred in 97% patients out of the hospital. The annual prevalence of severe hypoglycemia caused by sulphonyl ureas in T2DM is 7% [71].

**Hypoglycemia and T3cDM:** The T3cDM is associated with exocrine pancreas disorders [72,73]. Chronic pancreatitis (approximately 78.5% of all T3cDM) is the most common cause for T3cDM, while pancreatic cancer (approximately 8% of all T3cDM) is the second most common cause according to recent studies [74,75]. The glycemic control for patients with total pancreatectomy challenging, because of complete lack of both glucagon and insulin.
PDX1 and Insulin Regulation

**PDX1 regulates insulin expression**

Pancreatic and Duodenal home box 1 (PDX1), also known as Insulin Promoter Factor 1 (IPF1), is a home domain-containing transcription factor specific for pancreatic islet β cells. PDX1 functions as a master regulator for a variety of essential cellular events including embryonic pancreas development, maturation and stabilization of postnatal β cell functions [78-82]. PDX1 expression is firstly detected at embryonic day 8.5 in the dorsal and ventral buds that eventually fuse and give rise to pancreas. During embryonic development of pancreas, PDX1 is expressed in all precursor cells; while in the adult stage, PDX1 expression is more restricted to the nuclei of β cells and a small subpopulation of delta and PP cells in the islet [83]. It is known that PDX1 plays a central role in maintaining the mature β cell function and glucose metabolism through regulating the expression of multiple key endocrine β-cell-specific genes including insulin, glucokinase, islet amyloid polypeptide and the glucose transporter type 2 [84-89]. Deletion or homozygous inactive mutations in Pdx1 is lethal in mice due to whole pancreatic agenesis. Conditional knockout of Pdx1 gene in β cells of mice leads to overt diabetes, whereas knocking-down of Pdx1 expression results in decreased insulin secretion [90]. Pdx1 mutant zebra fish have the key diabetic features of reduced β cells, decreased insulin and elevated glucose levels [91]. In humans, heterozygous mutations in PDX1 have been associated with diabetes, including type 4 maturity-onset diabetes of the young (MODY IV) and non-MODY type 2 diabetes. In addition to diabetes, abnormal PDX1 is also involved in other Pathophysiological conditions, such as chronic pancreatitis with decreased PDX1 expression and others. Overall, PDX1 has been demonstrated to directly regulate glucose-dependent insulin expression and secretion.

**PDX1 is associated with PDAC and insulinomas**

PDX1 is mainly expressed and functions in islet β cells in adults. However, aberrant elevated PDX1 expression in pancreatic cancer and neuroendocrine tumors, including insulinoma, strongly suggested that PDX1 as a fundamental transcriptional factor for pancreas development may play an important role in tumorigenesis, especially in PDAC [92-94] and insulinoma [95,96]. PDX1 is able to promote Kras G12D oncogenic protein-induced development of PanIN, metaplasia and pancreatic ductal adenocarcinoma [97-99]. In addition, over expression of PDX1 in both benign cells (HEK293 and Human Pancreatic Ductal Cells), as well as pancreatic cancer cells (PANC1 and MiaPaca 2) and insulinoma cells (Min6 and βTC6 cells) lead to significant increases in cell proliferation, invasion and colony formation in vitro, as well as promotion of tumor growth in xenograft SCID mice [92,93,95]. Therefore, these studies suggest that PDX1 is involved in tumorigenesis of both PDAC and insulinoma.

A special type of pancreatic neuroendocrine tumor insulinomas, as well as lack of a third islet hormone, pancreatic polypeptide. Hypoglycemia frequently happens in these patients due to the brittleness of their glucose regulation [72,74,76]. Islet transplantation restores functioning islet and can successfully stabilize glucose homeostasis in post-pancreatitis my patients [77].

These patients with insulinoma suffer horribly from uncontrollable hypoglycemia for which there is no effective treatment, because the expanded β cell mass continues to secrete insulin and disrupt the glucose regulation, causing severe hyperinsulinemic hypoglycemia.

Residioablastosis in adults is a complication of Roux-en-Y gastric bypass surgery requiring recurrent hospitalizations for hyperinsulinemic hypoglycemia. Congenital residioablastosis is also commonly referred to as persistent hyperinsulinemic hypoglycemia of infancy. It is caused by a number of genetic mutations, and symptoms can range from mild to severe. Severe cases can manifest as cyanosis or seizures, which can then lead to developmental delay if brain damage occurs. The abnormal histologic aspects of the tissue included the presence of islet cell enlargement, islet cell dysplasia, β cells budding from ductal epithelium, and islets in opposition to ducts. Most congenital hyperinsulinism is caused by different mechanisms than excessive proliferation of β cells in a fetal pattern and the term fell into disfavor after it was recognized in the late 1980s that the characteristic tissue features were sometimes seen in pancreatic tissue from normal infants and even adults, and is not consistently associated with hyperinsulinemic hypoglycemia. As an important islet β cell specific transcription factor, PDX1 exerts its cellular functions under normal conditions by regulating expression of genes critical for insulin synthesis. In insulinoma cells, PDX1 was significantly over expressed in both human insulinoma specimens and mouse insulinoma cell line [95]. Knocking down of Pdx1 expression using bi-functional shRNA resulted in significant inhibition of insulin expression, Pdx1 expression and glucose-stimulated insulin secretion, as well as cell proliferation in mouse β TC6 cells. Nanoparticle capsulated bash RNA-mPDX1 prevented death from severe hyperinsulinemic hypoglycemia in insulinoma SCID mice (Figure 2) [95]. Overall, PDX1 plays a significant role in regulating insulin synthesis and the expression level correlates with its insulinoma. A novel therapeutic strategy targeting PDX1 gene has been proved effective in preventing mortality for hyperinsulinemic hypoglycemia in an insulinoma mouse model.

**Hypoglycemia Animal Models**

Severe hypoglycemia is a life-threatening disease; therefore hypoglycemic animal models are essential for designing and testing preventive and therapeutic treatments. So far, drug-induced hypoglycemic effects have been observed on multiple animal models,
including mouse, rat, rabbit, dog and pig. Insulin administration induced hypoglycemia remains the most frequently use approach in animal models. Fasting-induced hypoglycemia rat models have been generated and studied since 1970s [103-105]. It has been reported that other medications including metformin, GLP1 analogs, DPP4 inhibitors, methadone [106], sulfonylurea [107], and sunitinib [108] are known to trigger hypoglycemia in various animal models. Moreover, effects from herbal medicines exhibit hypoglycemic, including Cordyceps militaris [109], Camellia sinensis [110]. Besides, there were genetic engineered animal models reported to have moderate to severe hypoglycemia. Sstr5 gene knockout mice and Sstr1/5 double gene knockout mice demonstrated hyperinsulinemic hypoglycemia and improved glucose in tolerance associated with elevated islet PDX1 expression [111,112], suggesting that Sstr genes are negative regulators for PDX1 and controlling PDX1 expression level in islets is critical for prevention of hyperinsulinemic hypoglycemia [96,113-115]. Ubiquitous expression of the constitutively active form of Pik3ca (H1047R) leads to hypoglycemia and hypoinsulinemia in mice [116]. MiR-378/378* microRNA gene knockout display hypoglycemia and increased hepatic triglyceride level with enhanced insulin sensitivity in mice [117]. RIP-Tag2 transgenic mice develop pancreatic β cell tumors leading to progressive autonomous insulin secretion and hypoglycemia, which is lethal when these transgenic mice reach the age of 3 to 4 months [118]. Mouse insulinoma cell line NIT-1 and β TC6 were used to generate insulinoma SCID mouse models; when implanted within the peritoneal cavity, these mice uniformly succumb to hypoglycemia within a mean of 60 days and are therefore a mouse model to study the preventive and therapeutic strategies for severe hypoglycemia [113,119].

**PDX1 targeted therapy for hypoglycemia**

Unfortunately, there are no effective therapies for severe hypoglycemia caused by insulinoma and nesidioblastosis. Surgical removal of malignancy continues to be the treatment of choice because these tumors generally respond poorly to chemotherapy. Insulinoma is often characterized by elevated levels of circulating hormonal milieu of the endocrine pancreas, and the isolated perfused human pancreas. Pancreas. 2000; 21: 203-211.

Moreover, exacts from herbal medicines exhibit hypoglycemic effects, including Cordyceps militaris [109], Camellia sinensis [110]. Besides, there were genetic engineered animal models reported to have moderate to severe hypoglycemia. Sstr5 gene knockout mice and Sstr1/5 double gene knockout mice demonstrated hyperinsulinemic hypoglycemia and improved glucose in tolerance associated with elevated islet PDX1 expression [111,112], suggesting that Sstr genes are negative regulators for PDX1 and controlling PDX1 expression level in islets is critical for prevention of hyperinsulinemic hypoglycemia [96,113-115]. Ubiquitous expression of the constitutively active form of Pik3ca (H1047R) leads to hypoglycemia and hypoinsulinemia in mice [116]. MiR-378/378* microRNA gene knockout display hypoglycemia and increased hepatic triglyceride level with enhanced insulin sensitivity in mice [117]. RIP-Tag2 transgenic mice develop pancreatic β cell tumors leading to progressive autonomous insulin secretion and hypoglycemia, which is lethal when these transgenic mice reach the age of 3 to 4 months [118]. Mouse insulinoma cell line NIT-1 and β TC6 were used to generate insulinoma SCID mouse models; when implanted within the peritoneal cavity, these mice uniformly succumb to hypoglycemia within a mean of 60 days and are therefore a mouse model to study the preventive and therapeutic strategies for severe hypoglycemia [113,119].

**PDX1 targeted therapy for hypoglycemia**

Unfortunately, there are no effective therapies for severe hypoglycemia caused by insulinoma and nesidioblastosis. Surgical removal of malignancy continues to be the treatment of choice because these tumors generally respond poorly to chemotherapy. Agents (fuorouracil, doxorubicin, and streptozocin) [120]. PDX1 targeted therapies could provide an alternative strategy to conventional therapies [12,13]. For example insulinoma-specific cytoxicity using the suicide gene Thymidine Kinase (TK) driven by Rat Insulin Promoter (RIP), which is activated by PDX1 and antiviral drug Ganciclovir (GCV) delivered by a nontoxic, non-inflammatory liposomal delivery system, was successfully prevent hypoglycemic death in an insulinoma SCID mouse model [119]. Using liposomal delivery of RIP-TK resulted in euglycemia of the mice, whereas adenosivl delivery of RIP-TK causes significant hyperglycemia due to damage to the islets. More recently, a novel bi-functional shRNA nanoparticle targeting PDX1 significantly and effectively abated PDX1 in insulinoma and in pancreas islets, therefore reversed hypoglycemia in vivo in two mouse models [95,96,121,122]. Bi-functional shRNA nanoparticle prevented death from hypoglycemia in an insulinoma mouse model; glucose levels rose to 170mg/dl after three biweekly treatments then returned to normal by 90 days after treatment. In SSTR1/5-/- mice, fasting hypoglycemia was reversed by three biweekly treatments of bi-functional shRNA nanoparticles; glucose levels rose to slightly greater than 200mg/dl after treatment, the remarkably returned to euglycemia 90 days after therapy. Glucose levels before and after bi-shRNAmPDX1, shRNAmPDX1 and RIP-TK (GCV) treatments in two insulinoma-induced hypoglycemia mouse models are summarized in (Figure 2). These studies suggest that PDX1 targeted therapies could represent a promising therapy for severe hypoglycemia induced by insulinomas.

**Conclusion**

Severe hypoglycemia with extremely low blood glucose level is dangerous and a potential life-threatening condition. There are very limited therapeutic management options for multiple types of hypoglycemia and there are no effective therapies for hyperinsulinemic hypoglycemia due to malignant insulinoma and nesidioblastosis. PDX1 targeted therapies successfully restored glucose regulation in two mouse models of hypoglycemia and suggest a promising preventive and therapeutic strategy for severe hypoglycemia.

**References**


67. In Diabetes (Type 1 and Type 2) in Children and Young People: Diagnosis and Management, London, in press. 2015.


101. Reid MD, Balci S, Saka B, Adsay NV. Neuroendocrine tumors of the


